ASH: Argenx cues up a second use for efgartigimod
pharmaphorum
DECEMBER 12, 2022
Vyvgart is already approved to treat generalised myasthenia gravis, getting a green light for that indication from the FDA a year ago, and launched with a $225,000 per annum price tag in competition with rival gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).
Let's personalize your content